Clinical Vignette
A 78-year-old patient presented with New York Heart Association functional class II dyspnea complaints and suspected aortic stenosis. The patient was referred for transthoracic echocardiography which confirmed the presence of severe aortic stenosis secondary to a calcified (probably) bicuspid aortic valve (BAV) with a mean gradient of 22 mm Hg, peak gradient of 40 mm Hg, and calculated aortic valve area of 0.9 cm 2 ( Figure 1 ). The stroke volume was 34 mL/m 2 (body surface area, 1.68 m 2 ), and the left ventricular ejection fraction was 39%. On computed tomography (CT), the diagnosis of BAV was confirmed, whereas the aortic root and tubular part of the ascending aorta were slightly dilated (sinus of Valsalva, 42 mm; sinotubular junction, 39 mm; tubular ascending aorta, 42 mm; Figure 1 ). The logistic EuroSCORE II was 16%. Invasive coronary angiography excluded obstructive coronary artery disease needing revascularization. With the diagnosis of classical low-flow, low-gradient, severe aortic stenosis, the patient was referred for transcatheter aortic valve replacement (TAVR) after discussion in the Heart Team.
BAV is the most common congenital valvular heart defect, with a prevalence as high as 2% of the general population. 1 Among patients undergoing surgical aortic valve replacement for aortic stenosis, BAV can be present in as high as 49% of patients with 9% older than 80 years. 2 Currently, TAVR is an established therapy for patients with symptomatic severe aortic stenosis with high risk or contraindications for surgery. Landmark randomized trials have considered BAV as an exclusion criterion. However, large registries have shown that a significant number of patients with BAV have been treated with TAVR ( Figure 2) . [3] [4] [5] Compared with tricuspid aortic valve stenosis, TAVR in BAV stenosis has been associated with higher rates of paravalvular regurgitation, 30-day mortality rates, and likelihood of conversion to surgery. 6 New TAVR generation devices have been associated with lower rates of paravalvular regurgitation. 7 Implementation of CT to assess the geometry and dimensions of the aortic annulus has improved prosthesis sizing, thereby reducing the risk of paravalvular regurgitation or annulus rupture. 8 However, BAV is a heterogeneous disease with varying valve morphology (raphe versus nonraphe; asymmetrical cusp size), annulus geometry and size, asymmetrical calcification of the aortic valve and left ventricular outflow tract, frequently associated with anomalous origin of coronary arteries and various configurations of aortic root and ascending aorta that may challenge TAVR. In this specific group of patients, multimodality imaging is crucial for patient selection and choice of the most appropriate device to ensure procedural success (Table) .
In this review article, we aim to provide a detailed roadmap (using the 6 points put forward in Table) for the use of multimodality imaging to select patients with BAV stenosis for TAVR.
Aortic Valve Morphology Valve Configuration
A BAV is defined by the presence of 2 commissures in systole. However, the morphology of BAV is highly variable ranging from valves with 2 cusps and 2 commissures to valves with 3 cusps fused by 1 or 2 raphes that leave 2 or 1 commissures, respectively ( Figure 3 ). The completeness of the fusion raphe varies, and there may be incomplete raphes that challenge the diagnosis of the valve morphology. Cusp number and size, cusp position, number of commissures, and characteristics of aortic sinus and interleaflet triangles have been used to classify the BAV. 1 The classification of Sievers and Schmidtke, 9 based on surgical specimen, is frequently used (Figure 3 ; Movie I in the Data Supplement). Using the number of raphes, the BAV can be classified as type 0 (without raphe), type 1 (1 raphe), and type 2 (2 raphes). Within each category, the BAV phenotype was classified further based on the following criteria: the spatial position of the cusps and commissures (anteroposterior versus lateral) and valvular function (graded as predominantly regurgitation, predominantly stenosis, balanced regurgitation and stenosis, or no stenosis or regurgitation). Imaging for TAVR in BAV calcifications of the valve may challenge the diagnosis. Compared with CT, echocardiography has a lower accuracy to detect BAV. 10 Multidetector row CT (MDCT) is pivotal in the work-up for TAVR, and, based on the large variability in BAV configurations observed in a CT core laboratory, a new classification of BAV has been proposed. 8 This new classification takes into consideration the aortic valve morphology and its interaction with the deployed transcatheter valve at the aortic cusp plane (presence or absence of raphe) and at the commissural level (presence of 2 or 3 commissures; Figure 4 ). Tricommissural BAV (traditionally known as acquired or functional BAV) is characterized by 3 cusps with focal fusion of 3 commissures. Bicommissural raphe type is characterized by the presence of a true raphe, whereas the bicommissural nonraphe type has 2 cusps and 2 commissures. In addition, based on the leaflet orientation, the BAV is further classified as coronary cusp fusion (when the coronary arteries arise from the coronary sinuses of 2 fused cusps) and mixed cusp fusion (when the noncoronary cusp is fused with the left or the right coronary cusps and the coronary arteries arise from 2 independent coronary sinuses).
Valve Calcification
Cardiac CT is the imaging technique of reference to assess aortic valve calcification. In patients aged ≥80 years old, a study evaluating the characteristics of operatively excised stenotic valves showed that BAVs are heavier than tricuspid valves in men (3.61 versus 2.31 g) and women (2.62 versus 1.64 g), suggesting that the deposition of calcium and fibrotic tissue is higher in BAV. 11 The calcifications are most frequently observed in the cusps and raphe as viewed from the aortic side. The calcification of the aortic cusps is usually asymmetrical and the most often involved cusp is the left. 12 The amount and distribution of valve calcifications may pose challenges to transcatheter valve deployment. However, the new-generation devices have overcome the unfavorable anatomy of BAV. A recent large multicenter registry of TAVR in BAV patients has shown that the incidence of significant paravalvular regurgitation has decreased compared with the early-generation valves (from 8.5% to 0%; P<0.001).
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Assessment of Aortic Valve Function Aortic Valve Stenosis
Aortic stenosis is the most common complication of BAV. In a large series of excised stenotic aortic valves, bicuspid anatomy was present in 59% of patients aged ≤70 years and 41% of patients older than 70 years. 13 In contrast, aortic regurgitation is less frequently observed (43% of BAV patients undergoing aortic valve surgery). 14 Aortic stenosis is routinely assessed with transthoracic echocardiography, and the severity is based on peak jet velocity, mean transvalvular gradient, and effective orifice area calculated according to the continuity equation. 15 A peak jet velocity >4 m/s, mean gradient >40 mm Hg, and aortic valve area <1 cm 2 define severe aortic stenosis. However, a subgroup of patients may show inconsistently graded severe aortic stenosis: a tight aortic valve area but a low transvalvular gradient. This may relate to impaired left ventricular systolic function (classical low-flow, low-gradient, severe aortic stenosis) or reduced stroke volume in patients with a severely hypertrophied left ventricle and restrictive physiology or because of the presence of severe mitral valve disease (paradoxical low-flow, low-gradient, severe aortic stenosis). In addition, erroneous measurements of the left ventricular outflow tract diameter may result in a tight aortic valve area with a low gradient regardless of left ventricular ejection fraction. 16 The prevalence of inconsistently graded severe aortic stenosis among patients with BAV has not been reported. It is speculated that the asymmetrical distribution of valve calcification may lead to eccentric jets that challenge the alignment of the ultrasound beam and lead to underestimation of transvalvular gradients on continuous wave Doppler echocardiography. On the other hand, the left ventricular outflow tract in patients with BAV is significantly larger than in patients with tricuspid aortic valve. This may lead to a lower proportion of patients with discordantly graded severe aortic stenosis. Three-dimensional imaging techniques can aid in the identification of severe aortic stenosis. By aligning the multiplanar reformation planes across the tips of the aortic cusps, the anatomic aortic valve area can be accurately measured ( Figure 5 ). In addition, by incorporating the planimetered cross-sectional area of the left ventricular outflow tract obtained with 3-dimensional imaging techniques into the continuity equation, the grading of the aortic stenosis may change from severe to moderate. 16, 17 In patients with tricuspid severe aortic valve stenosis and preserved left ventricular . The valve morphology can be better visualized with 3-dimensional transesophageal echocardiography using the biplane view that provides the long-axis view of the valve (D) and the short-axis view of the aortic valve at the level of the tips of the cusps (E). However, in severely calcified valves, the calcifications create shadow on the edge of the cusps challenging the measurement of the anatomic valve area. On computed tomography, the anatomic aortic valve area can be assessed accurately (0.6 cm 2 , F). Imaging for TAVR in BAV ejection fraction, 33% of patients with low gradient would have been classified to moderate aortic stenosis if the MDCT derived left ventricular outflow tract area would have been included in the continuity equation. 16 However, a recent study showed that an aortic valve area ≤1.2 cm 2 measured on MDCT had similar prognostic value as an aortic valve area ≤1 cm 2 and suggested that the cutoff value to define severe aortic stenosis should be different based on the imaging method used. 17 Finally, the calcium load of the aortic valve as assessed with CT has been proposed as surrogate to grade aortic stenosis. For the same age and sex, it is well established that BAV has a larger calcium load than tricuspid aortic valves. 12 In addition, in patients older than 51 years, increasing aortic valve calcium load is significantly correlated with a higher mean transvalvular gradient. 18 However, the optimal threshold of aortic valve calcium load to define severe aortic stenosis in BAV has not been defined. How these novel imaging techniques may influence on the grading of aortic stenosis in BAV remains to be investigated.
Aortic Regurgitation
In BAV stenosis, mild or moderate aortic regurgitation is frequently present. The measures of aortic stenosis severity remain accurate even when aortic regurgitation is severe. However, for a given aortic valve area, the peak velocity and mean transvalvular gradient may be higher than expected because of the high transaortic volume flow rate. 19 Echocardiographic assessment of aortic regurgitation severity relies on color, continuous and pulsed wave Doppler parameters of the regurgitant jet along with evaluation of left ventricular volumes and function. 20 Color flow Doppler permits visual assessment of the regurgitant jet and informs about jet eccentricity. The ratio between the regurgitant jet width and the left ventricular outflow tract diameter is a semiquantitative parameter of aortic regurgitation severity. However, it assumes a circular regurgitant orifice which is not applicable in BAV anatomy. Therefore, this parameter should not be used in isolation in BAV aortic regurgitation. Instead, vena contracta width and quantification of the effective regurgitant orifice area and regurgitant volume with the proximal isovelocity surface area method are recommended to grade aortic regurgitation. 20 Although the vena contracta width can be applied to eccentric regurgitant jets, the feasibility of the proximal isovelocity surface area method is limited. The use of 3-dimensional imaging techniques such as echocardiography and cardiovascular magnetic resonance may improve the quantification of the effective Figure 6 ). 21 Finally, the measurement of the diastolic flow reversal in the descending aorta using pulsed wave Doppler recordings is a strong parameter to define severe aortic regurgitation. However, it may be affected by the aortic compliance and whether it concerns an acute or chronic regurgitation.
Aortic Annulus Geometry and Dimensions
Accurate preoperative assessment of the aortic annular dimensions is crucial for the success of TAVR because the choice of an incorrectly sized prosthesis may result in complications such as severe paravalvular regurgitation, prosthesis migration, and annulus rupture. According to current recommendations, the choice of prosthesis size is based on MDCT or 3-dimensional transesophageal echocardiography if MDCT is not feasible. 15 BAV is characterized by a larger annulus size and sinus of Valsalva with increased ascending aorta dimensions, when compared with tricuspid aortic valves. In addition, the BAV aortic annulus is less elliptical than the tricuspid valve annulus and shows more frequently eccentric calcifications. 22 In tricuspid aortic valves, the aortic annulus is commonly defined as the plane bisecting the most basal attachment points of the 3 cusps into the left ventricular outflow tract. However, with BAV anatomy, the 3 points that demark the annulus plane may be difficult to define. Particularly, in type 0 BAV, there are only 2 hinge points of the 2 existing cusps. The third point to define the annular plane will be derived from a plane perpendicular to the landing zone of the prosthesis (Figure 7) . Conversely, in type 1 BAV, the hinge points of the 3 cusps can be identified and the annulus plane can be defined conventionally ( Figure 7 ). To date, there is no established methodology to define the aortic annulus plane in BAV. In type 0 BAV, it could be hypothesized that the area enclosed between the commissures and the cusps in systole should be the area to be covered by the deployed transcatheter valve. However, in patients with severe BAV stenosis, this area may be difficult to determine, which can result in significant undersizing. In addition, there is little and inconsistent evidence on how the prosthesis frame is deployed in large cohorts of patients with BAV stenosis. In 11 patients with type 0 BAV (as assessed with transesophageal echocardiography) who received a balloon-expandable prosthesis, Wijesinghe et al 23 reported a circular deployment of the prosthesis frame in all patients. In contrast, Himbert et al 24 reported an elliptical deployment of the prosthetic frame as assessed with MDCT in 15 patients with BAV stenosis (most of them with type 1 BAV) who received a self-expandable prosthesis. Similarly, Hayashida et al 25 described an elliptical deployment of the prosthetic frame in 21 BAV stenosis patients (86% type 1 and 14% type 2, with 2 raphe) receiving a self-expandable (50%) or balloon-expandable (50%) prosthesis. The presence of a much calcified, thickened raphe may limit the deployment of the prosthetic frame. In addition, it remains unknown whether the deployment of the frame is homogeneous or more restrained at the level of the edge of the native aortic cusps when compared with the level of the annular plane. These observations suggest that the definition of the aortic annulus plane and measurement of the aortic annulus size are not the only factors to take into consideration when in the lower, left) . In B, the measurement of the aortic annulus of a type 1 BAV is presented. In this type of BAV, the hinge points of the right (red point), left (green point), and no-coronary (yellow point) cusps can be identified and the orthogonal planes cross the hinge points of the cusps (yellow arrows in the coronal plane-upper, left; red arrow in the sagittal plane-lower, left). Imaging for TAVR in BAV selecting the prosthesis type and size. Probably, the interaction between the BAV anatomy and the prosthesis type is more important for the final TAVR results than just the size of the aortic annulus. The landing zone that spans between the edges of the cusps until the left ventricular outflow tract should be considered, including the presence or absence of raphe and the calcium load (thickness) of the raphe.
Aortic Root and Ascending Aorta
Aortopathy BAV disease is not just confined to the valve cusps; the aorta is also abnormal, a condition known as bicuspid aortopathy, observed in ≈35% to 50% of patients. 26 Compared with adults with a tricuspid aortic valve, BAV patients have larger dimensions of the aortic sinuses and ascending aorta and are at risk for progressive aortic dilation because of abnormal aortic elasticity. 27 The average annual increase in aortic diameter ranges from 0.2 to 1.2 cm/y. The presence of a family history of aortic valve disease has shown to be significantly associated with increased risk of aortic dilation. 28 In addition, after aortic valve replacement, the thoracic aorta may continue to dilate and the risk of late dissection does not disappear. [29] [30] [31] Therefore, in patients with severe BAV stenosis and aortic dilation, the decision to perform TAVR without repairing the aorta should be weighed against the risk of aortic aneurysm formation and late aortic dissection.
Several patterns of aortic dilation have been described (Figure 8) . 32 Transthoracic echocardiography is the primary diagnostic tool for evaluation of BAV patients; however, it is unable to evaluate the entire ascending and descending aorta. Transesophageal echocardiography permits better definition of the aortic root and ascending aorta dimensions. However, this imaging modality is relatively invasive and is not suitable for patient surveillance. CT and magnetic resonance imaging are considered the reference standard to measure the aortic dimensions at different levels.
Current guidelines recommend aortic surgery in patients with BAV and an aortic diameter ≥55 mm; however, aortic surgery should be considered in patients with BAV and an aortic diameter ≥50 mm and additional risk factors (coarctation of the aorta, systemic hypertension, family history of dissection, or increase in aortic diameter 0.3 mm/y). 15 Recently, a cross-sectional area:height ratio >10 cm 2 /m measured at the level of the sinus of Valsalva or at the tubular ascending aorta has been associated with increased risk of type A dissection. 33 The presence of bicuspid aortopathy increases the risk of aortic dissection and rupture during balloon valvuloplasty or implantation of balloon-expandable valves. However, the true incidence of aortic complications in BAV patients remains unknown. It would be interesting to know whether a specific type of aortopathy may entail a higher complication risk during TAVR. In addition, the progression to aortic aneurysm and occurrence of late aortic dissection after TAVR have not been reported. 34 It may be difficult to demonstrate if these complications occurred in current series of BAV patients treated with TAVR because the frequency is relatively low (3%-9% for aortic aneurysm formation and 0.5%-1% for aortic dissection). 29, 31 In addition, these complications have been described over a mean follow-up of at least 10 years, but TAVR is a relatively new therapy and experiences with at 10 years of followup are anecdotal.
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Horizontal Aorta
One of the characteristics of patients with BAV stenosis is the presence of a horizontal aorta defined as an angle of <30° between the plane perpendicular to the aortic annulus plane and a horizontal reference line ( Figure 9 ). A horizontal aorta may complicate accurate positioning of the prosthesis during TAVR, particularly when using a self-expanding valve. Need of a second valve and postdilation, longer fluoroscopy time and increased device embolization, and mild or greater than mild paravalvular regurgitation have been described. 35 Accordingly, balloon-expanding valves may be preferred in patients with BAV stenosis and horizontal aorta. Moreover, calcified aortic wall (porcelain aorta) is more frequent in horizontal aortas. The presence of significant calcifications of the ascending aorta limits the capability to control the tension on the delivery catheter during the device release and may lead to implantation failure. 36 Therefore, delivery through the MDCT imaging of the aortovalvular complex has become a prerequisite for procedural planning with self-expanding TAVR in patients with horizontal aorta.
Coronary Arteries: Height and Location of Ostia
The presence of significant coronary artery stenosis should be evaluated with invasive coronary angiography before TAVR. However, to assess the risk of occlusion of the coronary ostia by one of the aortic cusps during TAVR, MDCT provides better spatial resolution to measure the height of the coronary ostia relative to the annulus plane. 37 The estimated incidence of this complication is 0.7%, and the 30-day mortality is as high as 41%. 37, 38 Coronary artery obstruction is more frequently observed in the left main coronary artery and occurs because of the displacement of a bulky calcified aortic cusp into the ostium of the coronary artery by the deployed transcatheter aortic valve. 37 Low height of the coronary ostia (<12 mm), narrow sinus of Valsalva (<30 mm), use of balloon-expandable valves, and valve-in-valve procedures are associated with increased risk of coronary obstruction. 37, 38 In the largest registry of BAV stenosis patients treated with TAVR, the incidence of coronary obstruction was 0.9%. 34 Patients with BAV are known to have more frequent coronary artery anomalies when compared with patients with tricuspid aortic valves. A recent study evaluating the coronary artery anatomy on MDCT of 186 patients with BAV showed that patients with BAV without raphe had left dominance more frequently than patients with BAV with raphe (48% versus 26%; P=0.047). 39 In addition, separate ostia for the left anterior descending and circumflex coronary arteries were observed in 28% of patients with BAV without raphe compared with 9% of patients with BAV with raphe (P=0.016). However, it remains unknown whether the height of the coronary ostia of patients with BAV stenosis (Figure 10 ) is different from that of patients with tricuspid aortic valve stenosis.
The larger sinus of Valsalva of patients with BAV stenosis compared with tricuspid aortic valve stenosis would suggest that BAV patients may be protected from coronary obstruction during TAVR. However, the evidence does not confirm this hypothesis as the incidence of coronary obstruction was similar in BAV and tricuspid aortic valve stenosis.
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Implications for Prosthesis Type Selection
The technological development of TAVR devices has led to improved results with lower rates of significant paravalvular regurgitation and annulus rupture, conversion to surgery, vascular complications and bleeding, coronary artery obstruction, stroke, and 30-day mortality, whereas the incidence of permanent pacemaker implantation remained unchanged. In addition, the use of 3-dimensional imaging techniques, particularly MDCT, to accurately size the aortic annulus and select the prosthesis size and evaluate the procedural access has also contributed to the improved results. These observations are common to tricuspid aortic valve stenosis and BAV stenosis. The international registry on TAVR in BAV stenosis reported no significant paravalvular regurgitation when newgeneration devices (SAPIEN 3 [Edwards Lifesciences Corporation, Irvine, CA] and Lotus [Boston Scientific Corporation, Marlborough, MA]) were implanted compared with 8.5% incidence of paravalvular regurgitation when early-generation devices were used (SAPIEN XT and Corevalve [Medtronic, Minneapolis, MN]). 7 In addition, the use of new-generation devices was associated with a reduction in the incidence of annulus rupture (from 2% to 1%), conversion to surgery (from 4% to 1%), and major vascular complications (from 4.5% to 2.9%). Interestingly, the incidence of pacemaker implantation increased (from 13.1% to 16.7%), but this trend was similar in BAV stenosis and in tricuspid valve stenosis. 34 When analyzing the results according to the type of BAV, moderate or severe paravalvular regurgitation occurred only in patients with type 1 BAV treated with early-generation devices (most frequently with the Corevalve, 15.9%) and annulus rupture occurred only in patients with type 1 BAV and heavily calcified raphe (most frequently when using the SAPIEN XT valve, 6.0%). The design of new-generation devices, including outer sealing systems, and the increasing use of MDCT to size the aortic annulus have most probably contributed to the disappearance of significant paravalvular regurgitation. In addition, the improved anchoring systems of the new-generation devices permit more accurate selection of the prosthesis size, reducing significant oversizing and the risk of aortic annulus rupture. This evidence supports future use of TAVR in BAV stenosis. New-generation devices seem to overcome the anatomic challenges that BAV poses. Balloon-expandable valves such as the SAPIEN 3 and repositionable and retrievable valves such as the Lotus system are both suited for BAV. Future research will provide additional information on the incidence of bicuspid aortopathy after TAVR and valve durability, important questions that will impact on the expansion of this therapy to younger and lower risk patients in whom the prevalence of BAV is expected to be higher. The use of 3-dimensional imaging techniques such as MDCT will remain key in the selection of BAV patients for TAVR and probably in the follow-up (risk of aortopathy).
Conclusions
With an increasing use of TAVR in intermediate-and low-risk patients with severe aortic stenosis, BAV stenosis is becoming an important challenge. Advances in transcatheter valve design and 3-dimensional imaging techniques, particularly MDCT, have helped to improve the therapeutic results in this subgroup of patients.
In this article, we have introduced a practical roadmap for the imaging clinician to evaluate BAV patients who may be candidates for TAVR.
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